According to new American Gastroenterological Association guidelines on use of biomarkers to help manage Crohn disease endoscopic evaluation to rule out active inflammation after resolution of symptoms and normalization of biomarkers should occur:
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.